Corneal Ulcer Clinical Trial
Official title:
AONDA Therapeutic Indication Study I
NCT number | NCT05891106 |
Other study ID # | CLD265-P002 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 28, 2023 |
Est. completion date | July 10, 2023 |
Verified date | July 2023 |
Source | Alcon Research |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will be used to support assessment of AIR OPTIX® NIGHT & DAY® AQUA (AONDA) Soft Contact Lenses' safety and performance in accordance with updated European Union Medical Device Regulation (EU MDR) requirements.
Status | Completed |
Enrollment | 55 |
Est. completion date | July 10, 2023 |
Est. primary completion date | July 10, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - Diagnosis of a corneal condition with pain for which AONDA Soft Contact Lens as a therapeutic contact lens was placed on one or both eye(s) at Baseline. - Baseline and Follow-up (up to 1 year from Baseline) charts available. - Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: - Had a condition (pathological, behavioral, and/or situational) that contraindicated therapeutic contact lens wear or confounds study results during the data collection period, as determined or known by the Investigator. - Used systemic or ocular medication that would confound study results during the data collection period, as determined or known by the Investigator. - Other protocol-defined exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
United States | Franklin Park Eye Center PC | Franklin Park | Illinois |
United States | Optometry Group, PLLC | Memphis | Tennessee |
United States | Vision Health Institute | Orlando | Florida |
Lead Sponsor | Collaborator |
---|---|
Alcon Research |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in corneal pain at the Follow-up Visit | The Investigator will review the subject's chart and document change from baseline in corneal pain at the Follow-up visit as "improved, similar, or worsened." The Baseline Visit is defined as the first visit where the AONDA therapeutic contact lens was placed on eye as part of a treatment plan for an ocular condition. The Follow-up Visit is defined as the first visit where the AONDA therapeutic contact lens was removed from the eye, or the first visit following the removal of the contact lens if, for example, the contact lens was removed between visits. | Baseline, Follow-Up Visit (up to 1 year following the Baseline Visit) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05705024 -
Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells
|
Phase 2 | |
Completed |
NCT02731638 -
Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
|
Phase 3 | |
Completed |
NCT00324168 -
Steroids for Corneal Ulcers Trial
|
Phase 4 | |
Completed |
NCT04484402 -
Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells
|
Phase 1/Phase 2 | |
Completed |
NCT04820010 -
Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
|
||
Recruiting |
NCT02570321 -
Cross-linking for Corneal Ulcers Treatment Trial
|
Phase 4 | |
Completed |
NCT00386958 -
A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers
|
Phase 2 | |
Completed |
NCT04054817 -
ACRO Biocornea Clinical Trial in Taiwan
|
N/A | |
Completed |
NCT00997035 -
The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo
|
Phase 3 | |
Completed |
NCT02277054 -
Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty
|
N/A | |
Recruiting |
NCT05313828 -
Effect of Various Treatment Modalities on Dendritic Vial Ulcer
|
||
Recruiting |
NCT05255107 -
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers
|
Phase 2/Phase 3 | |
Recruiting |
NCT05255016 -
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers
|
Phase 2/Phase 3 | |
Terminated |
NCT00789646 -
Painless Subconjunctival Antibiotic and Antifungal Injection in Corneal Ulcer Patients
|
N/A | |
Not yet recruiting |
NCT05940376 -
Topical Insulin in Neurotrophic Keratopathy After Diabetic Vitrectomy
|
||
Completed |
NCT05200000 -
Wharton's Jelly Eye Drops in the Treatment of Chronic Keratitis
|
Phase 1 | |
Completed |
NCT01756456 -
Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01969786 -
Village Integrated Eye Workers Trial
|
N/A | |
Completed |
NCT01794312 -
Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
|
Phase 3 | |
Completed |
NCT04837534 -
Improving the Follow up Rate for Pediatric Patients
|
N/A |